Ozempic is a drug for diabetes, but it's also being used off-label for weight loss. Its active ingredient has inspired a new ...

It’s that time of the year; We all likely indulged more than we’d like to admit for the holidays and put on a few extra ...

As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...

The Ozempic maker's stock tanked after its highly anticipated CagriSema drug trial showed an average of 22.7% weight loss, ...

Hollywood is abuzz with allegations of “Ozempic face,” a term for “gaunt” features linked to rapid weight loss. Stars like ...

Novo Nordisk's CagriSema, a combination drug for weight loss, matches Lilly's Zepbound in late-stage trial, but doesn't surpass it. Stock falls 19% on news.

Shares in Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight-loss treatments Ozempic and Wegovy, plunged ...

Investors appeared disappointed by CagriSema’s Phase III readout, which showed weight loss that fell short of Novo Nordisk’s ...

Novo Nordisk’s stock dives as new weight loss drug disappoints in a late-stage trial, which gave a boost to Eli Lilly shares.

The outcome falls short of the 25% weight loss Novo Nordisk had expected and dents its chances of becoming the company's next blockbuster drug after Ozempic and Wegovy.

Shares in the company dived after a new anti-obesity treatment missed expectations in a study, denting its chances of ...